A phase 2 study evaluated the use of ruxolitinib plus standard GVHD prophylaxis in patients with myelofibrosis undergoing ...
News Medical on MSN10h
A step toward precision medicine: New drug targets for heart failureA groundbreaking study in Nature Cardiovascular Research uncovers promising drug targets for heart failure (HF) and its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback